Venture Capital Firm I Home
Innovation.
Clarity.
Execution.
A Venture Capital Firm for Visionary Innovators.
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.
We are a highly experienced team with a long-standing track record of entrepreneurial and investment success. We do this by turning break-through science into approved medicines or medical products.
We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
About
As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.
We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.
Team
Innovation.
We are backing exceptional innovation early.
Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A.
As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year.
Portfolio
Latest Press Releases
F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the US
Press Release. F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the US Financing is being led by new investor…
Read More
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Press Release. Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma Bel-sar Demonstrated 80% Tumor Control Rate, 90%…
Read More
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
Press Release. Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer 3 September 2024 The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted…
Read More
